Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102057 | 0.87 | MEN1 (0.60) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL1102265 | 0.85 | KMT2A (0.61) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL9972284 | 0.85 | MEN1 (0.56) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL1102089 | 0.84 | MEN1 (0.55) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL2626034 | 0.83 | SCN9A (0.47) | SCN3ASCN9ASCN5A | |
| SCHEMBL10310724 | 0.83 | SCN9A (0.47) | SCN3ASCN9ASCN5A | |
| SCHEMBL1102114 | 0.83 | KMT2A (0.61) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL9972249 | 0.82 | MEN1 (0.55) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL1091270 | 0.82 | MEN1 (0.60) | ALDH1A1TDP1KDM4EKMT2AMEN1 | |
| SCHEMBL10165439 | 0.82 | GPR27 (0.40) | KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | ALDH1A1 2811/4885TDP1 2356/4885KDM4E 2385/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | ALDH1A1 2811/4885TDP1 2356/4885KDM4E 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.